{
  "trial_id": "NCT00785291",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, race, ethnicity, ECOG performance status, HER2 status, estrogen receptor status, progesterone receptor status, prior chemotherapy, prior hormonal therapy, prior radiotherapy, prior trastuzumab or lapatinib treatment, prior bevacizumab treatment, measurable disease status, pre-existing peripheral neuropathy status, pregnancy status, history of hypersensitivity to paclitaxel or Cremophor EL, history of abdominal fistula or intra-abdominal abscess, history of gastrointestinal perforation, history of significant bleeding episodes, history of cardiovascular disease, anticoagulant use, history of stroke or transient ischemic attack, history of seizures, CNS metastases status, presence of non-healing wound, ulcer or bone fracture, life expectancy, granulocyte count, platelet count, creatinine level, bilirubin level, transaminase levels, urine protein level.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Prior Adjuvant Taxane",
          "prior chemotherapy"
        ],
        [
          "Hormone Receptor Status",
          "estrogen receptor status"
        ],
        [
          "Physician's Decision to use Bevacizumab",
          "prior bevacizumab treatment"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "HER2 status",
        "progesterone receptor status",
        "prior hormonal therapy",
        "prior radiotherapy",
        "prior trastuzumab or lapatinib treatment",
        "measurable disease status",
        "pre-existing peripheral neuropathy status",
        "pregnancy status",
        "history of hypersensitivity to paclitaxel or Cremophor EL",
        "history of abdominal fistula or intra-abdominal abscess",
        "history of gastrointestinal perforation",
        "history of significant bleeding episodes",
        "history of cardiovascular disease",
        "anticoagulant use",
        "history of stroke or transient ischemic attack",
        "history of seizures",
        "CNS metastases status",
        "presence of non-healing wound",
        "ulcer or bone fracture",
        "life expectancy",
        "granulocyte count",
        "platelet count",
        "creatinine level",
        "bilirubin level",
        "transaminase levels",
        "urine protein level"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Estrogen Receptor Status, Progesterone Receptor Status, HER2/Neu Status, ECOG Performance Status, Prior Chemotherapy, Prior Radiotherapy, Prior Hormonal Therapy, Prior Trastuzumab or Lapatinib, Prior Bevacizumab, Measurable Disease, Peripheral Neuropathy Grade, Granulocyte Count, Platelet Count, Creatinine Level, Bilirubin Level, Transaminases (AST, ALT), Urine Protein,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Prior Adjuvant Taxane",
          "Prior Chemotherapy"
        ],
        [
          "Hormone Receptor Status",
          "Estrogen Receptor Status"
        ],
        [
          "Physician's Decision to use Bevacizumab",
          "Prior Bevacizumab"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Progesterone Receptor Status",
        "HER2/Neu Status",
        "ECOG Performance Status",
        "Prior Radiotherapy",
        "Prior Hormonal Therapy",
        "Prior Trastuzumab or Lapatinib",
        "Measurable Disease",
        "Peripheral Neuropathy Grade",
        "Granulocyte Count",
        "Platelet Count",
        "Creatinine Level",
        "Bilirubin Level",
        "Transaminases (AST, ALT)",
        "Urine Protein"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Eastern Cooperative Oncology Group (ECOG) Performance Status, Estrogen Receptor Status, Progesterone Receptor Status, HER2/Neu Status, Prior Chemotherapy, Prior Hormonal Therapy, Prior Trastuzumab or Lapatinib, Prior Bevacizumab, Prior Radiotherapy, Body Mass Index, Systolic Blood Pressure, Diastolic Blood Pressure, Creatinine, Bilirubin, Transaminases (AST, ALT), Granulocytes, Platelet Count.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Prior Adjuvant Taxane",
          "Prior Chemotherapy"
        ],
        [
          "Hormone Receptor Status",
          "Estrogen Receptor Status"
        ],
        [
          "Physician's Decision to use Bevacizumab",
          "Prior Bevacizumab"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Eastern Cooperative Oncology Group (ECOG) Performance Status",
        "Progesterone Receptor Status",
        "HER2/Neu Status",
        "Prior Hormonal Therapy",
        "Prior Trastuzumab or Lapatinib",
        "Prior Radiotherapy",
        "Body Mass Index",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "Creatinine",
        "Bilirubin",
        "Transaminases (AST, ALT)",
        "Granulocytes",
        "Platelet Count"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, ECOG performance status, HER2/neu status, ER status, PgR status, stage of disease, presence of measurable disease, number of metastatic sites, prior adjuvant/neoadjuvant therapy, prior hormonal therapy, prior trastuzumab or lapatinib therapy, prior bevacizumab therapy.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "Prior Adjuvant Taxane",
          "prior adjuvant/neoadjuvant therapy"
        ],
        [
          "Hormone Receptor Status",
          "ER status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment",
        "Physician's Decision to use Bevacizumab"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "HER2/neu status",
        "PgR status",
        "stage of disease",
        "presence of measurable disease",
        "number of metastatic sites",
        "prior hormonal therapy",
        "prior trastuzumab or lapatinib therapy",
        "prior bevacizumab therapy"
      ]
    }
  }
}